The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects
A web-based survey of 452 English-speaking adults found mescaline was typically used infrequently for spiritual or nature-related reasons and produced moderate mystical-type acute effects with minimal challenging effects and few reported legal, psychological or medical harms. About half of respondents had a psychiatric condition and most (>67%) reported improvements after their most memorable mescaline experience, with no differences in effect intensity across mescaline sources, suggesting low abuse potential.
Authors
- Christopher Timmermann
- Johannes Ramaekers
- Alan Davis
Published
Abstract
Background
Mescaline is a naturally occurring psychoactive phenethylamine found in several cacti and historically used ceremonially by Indigenous and Latin American populations. Broader recognition of its possible therapeutic value in Western science began in the 1950s; however, knowledge of the safety profile of mescaline and the extent of its use remains limited. The primary aim of this study is to examine the epidemiology of mescaline use among English-speaking adults.
Methods
About 452 respondents completed a web-based survey designed to assess their previous experience with mescaline (subjective effects, outcome measures, and mescaline type used).
Results
Most respondents reported that they had consumed mescaline infrequently (⩽once/year), for spiritual exploration or to connect with nature (74%). A small number of respondents reported drug craving/desire (9%), whereas very few reported legal (1%), or psychological problems (1%) related to its use, and none reported seeking any medical attention. Overall, respondents rated the acute mystical-type effects as “ moderate,” ego-dissolution and psychological insight effects as “ slight,” and challenging effects as “ very slight.” Most respondents reported that they used Peyote and San Pedro in their most memorable mescaline experience. Overall, the intensity of acute mescaline effects did not differ between mescaline types. About 50% of the sample reported having a psychiatric condition (i.e. depression, anxiety, etc.), and most (>67%) reported improvements in these conditions following their most memorable experience with mescaline.
Conclusion
Findings indicate that the mescaline in any form may produce a psychedelic experience that is associated with the spiritual significance and improvements in the mental health with low potential for abuse.
Research Summary of 'The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects'
Introduction
Mescaline (3,4,5-trimethoxyphenethylamine) is a naturally occurring psychedelic phenethylamine found primarily in cacti such as Peyote (Lophophora williamsii) and San Pedro (Trichocereus pachanoi). The introduction summarises pharmacology (primarily 5-HT2A receptor modulation), typical oral dosing (synthetic mescaline ~200–400 mg), duration (peak ~2 h, total 8–12 h), rapid tolerance and low dependence liability, and a long history of ceremonial use among Indigenous peoples. Despite preclinical work and case reports describing visual, emotional and occasionally challenging effects, the authors note a lack of epidemiological data on patterns of use, subjective acute and enduring effects, and harms or benefits of mescaline in broader populations. Vedøy Uthaug and colleagues set out to fill this gap by conducting an international, web-based epidemiological survey of English-speaking adults who had used mescaline at least once. The primary aim was to characterise patterns and motivations for mescaline use, the acute subjective experience and enduring effects, and perceived harms or benefits. Secondary aims included assessing whether medical or psychological functioning changed after use and whether subjective effects or use patterns differed by mescaline type (synthetic, extracted, Peyote, or San Pedro).
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Uthaug, M. V., Davis, A. K., Haas, T. F., Davis, D., Dolan, S. B., Lancelotta, R., Timmermann, C., & Ramaekers, J. G. (2022). The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal of Psychopharmacology, 36(3), 309-320. https://doi.org/10.1177/02698811211013583
References (29)
Papers cited by this study that are also in Blossom
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Cohen, S. · Journal of Nervous and Mental Disease (1980)
Davis, A. K., Streeter Barrett, F., Griffiths, R. R. et al. · Journal of Psychopharmacology (2021)
Davis, A. K., Barsuglia, J. P., Lancelotta, R. et al. · Journal of Psychopharmacology (2018)
Davis, A. K., So, S., Lancelotta, R. et al. · The American Journal of Drug and Alcohol Abuse (2019)
Delgado, P. L., Moreno, F. A. · Journal of Psychoactive Drugs (1998)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Garcia-Romeu, A., Davis, A. K., Griffiths, R. R. et al. · Frontiers in Psychiatry (2020)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Show all 29 referencesShow fewer
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Halpern, J. H., Sherwood, A. R., Hudson, J. I. et al. · Biological Psychiatry (2005)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)
Luke, D. P., Terhune, D. B. · Frontiers in Psychology (2013)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Mason, N. L., Mischler, E., Uthaug, M. V. et al. · Journal of Psychoactive Drugs (2019)
Nour, M. R., Evans, J., Carhart-Harris, R. L. · Journal of Psychoactive Drugs (2017)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Ray, T. S. · PLOS ONE (2010)
Rickli, A., Luethi, D., Reinisch, J. et al. · Neuropharmacology (2015)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)
Talin, P., Sanabria, E. · International Journal of Drug Policy (2017)
Uthaug, M. V., Lancelotta, R., van Oorsouw, K. et al. · Psychopharmacology (2019)
Winkelman, M. J. · Current Drug Abuse Reviews (2014)
Cited By (15)
Papers in Blossom that reference this study
O’Mahony, B., Harrington, C., Harkin, A. et al. · Journal of Psychopharmacology (2026)
Kvam, T-M., Uthaug, M. V., Andersen, K. A. A. et al. · Frontiers in Psychiatry (2023)
Ley, L., Holze, F., Arikci, D. et al. · Neuropsychopharmacology (2023)
Luke, D., Gandy, S., Irvine, A. et al. · Psychoactives (2023)
Jones, G. M., Lipson, J., Wang, E. · Scientific Reports (2023)
Rabinowitz, J., Lev-Ran, S., Gross, R. · Frontiers in Psychiatry (2023)
Bohn, A., Kiggen, M. H. H., Uthaug, M. V. et al. · International Journal for the Psychology of Religion (2022)
Ortiz Bernal, A. M., Raison, C. L., Lancelotta, R. et al. · Frontiers in Psychiatry (2022)
Narine, K., Campbell, I., Dyck, J. et al. · Neuropharmacology (2022)
Glynos, N., Fields, C. W., Barron, J. et al. · Journal of Psychoactive Drugs (2022)
Show all 15 papersShow fewer
Orłowski, P., Ruban, A., Szczypiński, J. et al. · Journal of Psychopharmacology (2022)
Raison, C. L., Jain, R., Jain, S. et al. · Frontiers in Psychiatry (2022)
Balaet, M. · Frontiers in Neuroscience (2022)
Jones, G. M., Nock, M. K. · Scientific Reports (2022)
Yaden, D. B., Berghella, A. P., Regier, P. S. et al. · International Journal of Drug Policy (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.